LOMBARDI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 3.801
EU - Europa 554
AS - Asia 231
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
SA - Sud America 2
Totale 4.592
Nazione #
US - Stati Uniti d'America 3.798
IT - Italia 251
CN - Cina 204
SE - Svezia 79
FI - Finlandia 77
DE - Germania 39
IE - Irlanda 36
GB - Regno Unito 26
ES - Italia 12
VN - Vietnam 11
FR - Francia 8
IN - India 8
UA - Ucraina 6
BE - Belgio 3
CA - Canada 3
CZ - Repubblica Ceca 3
NL - Olanda 3
PL - Polonia 3
AT - Austria 2
EU - Europa 2
HU - Ungheria 2
KR - Corea 2
SG - Singapore 2
AU - Australia 1
EE - Estonia 1
GE - Georgia 1
HK - Hong Kong 1
JP - Giappone 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.592
Città #
Fairfield 657
Chandler 424
Woodbridge 395
Houston 325
Ashburn 313
Ann Arbor 309
Cambridge 246
Seattle 245
Wilmington 203
San Diego 60
Des Moines 54
Princeton 52
Beijing 51
Helsinki 49
Medford 46
Padova 45
Dublin 36
Boardman 25
Milan 23
Roxbury 23
Nanjing 20
Jinan 18
Jacksonville 15
Shenyang 13
Bologna 12
Falls Church 11
Nanchang 11
New York 11
Florence 10
Dong Ket 9
Hebei 7
Redwood City 7
Cagliari 6
Felanitx 6
Hangzhou 6
Tianjin 6
Turin 6
Jiaxing 5
London 5
Norwalk 5
Pescara 5
Rome 5
Zhengzhou 5
Guangzhou 4
Hefei 4
Lastra a Signa 4
Los Angeles 4
Ningbo 4
Tappahannock 4
Veronella 4
Washington 4
Ancona 3
Borås 3
Caldogno 3
Changsha 3
Fuzhou 3
Haikou 3
Kaiserslautern 3
Kilburn 3
Prague 3
Vicenza 3
Andria 2
Angri 2
Badalona 2
Barcelona 2
Budapest 2
Caprino Veronese 2
Catania 2
Cepagatti 2
Chicago 2
Conversano 2
Empoli 2
Forlimpopoli 2
Genoa 2
Hanoi 2
Hounslow 2
Kunming 2
Lanzhou 2
Lozzo di Cadore 2
Mestrino 2
Minneapolis 2
Modena 2
Motta Sant'Anastasia 2
Ogden 2
Omegna 2
Ravenna 2
Rieti 2
San Jose 2
San Pietro in Casale 2
San Severo 2
Segrate 2
Shanghai 2
Taiyuan 2
Taizhou 2
Terni 2
Ulju-gun 2
Vercelli 2
Vienna 2
Waanrode 2
Asunción 1
Totale 3.924
Nome #
2-Hydroxyglutarate as a biomarker in glioma patients 237
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up 171
Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma 163
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155) 155
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials 145
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor 133
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas 128
Perioperative multidisciplinary management of endoscopic transsphenoidal surgery for sellar lesions: practical suggestions from the Padova model 125
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. 120
5-aminolevulinic Acid fluorescence in high grade glioma surgery: surgical outcome, intraoperative findings, and fluorescence patterns. 119
Early recognition of aggressive pituitary adenomas: a single-centre experience 113
An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab. 110
Multifocal presentation of medulloblastoma in adulthood 104
Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: A phase II study with pharmacokinetic analysis 102
Predictive value of intraoperative 5-aminolevulinic acid-induced fluorescence for detecting bone invasion in meningioma surgery. 99
Annexin 2A sustains glioblastoma cell dissemination and proliferation 99
Surgery on motor area metastasis 98
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases 97
Pegylated Liposomal Doxorubicin and Gemcitabine in Patients With Advanced Hepatocellular Carcinoma Results of a Phase 2 Study 97
5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature 96
Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. 95
Open Transcranial Resection of Small (<35 mm) Meningiomas of the Anterior Midline Skull Base in Current Microsurgical Practice 95
Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic Approaches 95
Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma 93
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma 92
Cognitive and emotive state in elderly treatment-naïve patients with advanced cancer compared with an elderly healthy control population 91
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study 90
An update on targeted therapy in metastatic renal cell carcinoma 88
Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma 85
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? 84
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma 81
Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). 81
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology) 76
Comparison between18F-Dopa and 18F-Fet PET/CT in patients with suspicious recurrent high grade glioma: A literature review and our experience 76
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab 75
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature 69
Predictive role of MGMT status in recurrent glioblastoma (GBM) patients (PTS) treated with antiangiogenic drug (AD) plus temozolomide (TMZ) or CPT-11 66
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study 66
Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma 64
Efficacy and safety of radiotherapy (RT) plus temozolomide (TMZ) in elderly patients (EP) with glioblastoma (GBM) 60
DIAGNOSTIC VALUE OF PLASMA AND URINARY 2-HYDROXYGLUTARATE TO IDENTIFY PATIENTS WITH IDH-MUTATED GLIOMA 60
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 59
Cilengitide in bevacizumab-refractory high-grade glioma: Two case reports and critical review of the literature 57
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. 55
Assessing Response Using (99m) Tc-MIBI Early after Interstitial Chemotherapy with Carmustine-Loaded Polymers in Glioblastoma Multiforme: Preliminary Results. 52
Suspicious for recurrent low and high grade glioma and indeterminate MRI: the role of 18F-DOPA PET/CT 50
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes 45
Multifocal Medulloblastoma in an Adult Patient: Description of a Rare Presentation and Review of the Literature 35
An Overview of Intracranial Ependymomas in Adults 25
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study 23
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review 20
Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care 16
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification 14
The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation 11
Totale 4.655
Categoria #
all - tutte 16.677
article - articoli 16.137
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.814


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019240 0 0 0 0 0 0 0 0 0 0 132 108
2019/20201.030 97 42 31 203 80 55 97 98 114 106 67 40
2020/2021711 35 72 24 47 25 20 34 92 78 149 84 51
2021/2022848 25 54 104 72 83 49 77 98 30 21 60 175
2022/2023804 118 105 25 124 97 121 4 65 81 16 29 19
2023/2024470 24 90 65 40 41 66 53 38 23 29 1 0
Totale 4.655